FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

3,819 letters. Newest first.

  1. Aytu Biopharma

    FDA warned Aytu Biopharma that sponsored links for ADHD drug Adzenys XR-ODT are false or misleading because they omit risk information.

    High risk
  2. JulyMD

    FDA warned JulyMD that its website sold compounded semaglutide with misleading claims comparing it to Wegovy and Ozempic.

    High risk
  3. Slendid

    FDA warned Slendid that its website sells compounded semaglutide and tirzepatide with a false "clinically proven" claim, making the drugs misbranded.

    Medium
  4. Hello Cake, Inc. dba Hello Cake

    FDA warns Hello Cake, an online telehealth seller, that its website misbrands compounded sildenafil and tadalafil ED drugs as equivalent to Viagra and Cialis.

    Medium
  5. Biopreventative Company LLC dba Biopreventative

    FDA told Biopreventative its website claim that compounded tadalafil is "commonly known as Cialis" misbrands the drug.

    Low
  6. Sprout Health Partners LLC dba Sprout Health

    FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.

    Low
  7. Master Pharmaceuticals Group

    FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.

    High risk
  8. TRYM Health, Inc. dba TRYM Health

    FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.

    Medium
  9. HealBerry

    FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.

    Medium
  10. Reset IV, LLC dba Reset IV

    FDA warned Reset IV that its website misbrands compounded semaglutide and tirzepatide by claiming they are the same as FDA-approved drugs.

    Medium
  11. Yangzhou Yulou Paper Products Co., Ltd.

    FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.

    High risk
  12. bettyvape.com

    Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

  13. inspire.clinic

    FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.

    Low
  14. Bioverse, Inc. dba Bioverse

    FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.

    Low
  15. SimpleRx

    FDA warned SimpleRx that its website falsely implied compounded semaglutide and tirzepatide were Ozempic or Zepbound.

    High risk
  16. Elevate Your Wellness LLC, dba Elevated

    FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.

    Low
  17. Cosmo Medical Spa dba Cosmo Med Spa

    FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.

    Medium
  18. EvoLife Wellness

    FDA warned EvoLife Wellness that its website wrongly calls compounded semaglutide and tirzepatide "FDA-Approved," making the drugs misbranded.

    Medium
  19. eDrugstore

    FDA warns eDrugstore over claims that compounded tirzepatide is FDA-approved, making drugs misbranded (falsely promoted).

    High risk
  20. Nuvo Life Health Inc. dba Nuvo Life Health

    FDA warned Nuvo Life Health that its website sold compounded semaglutide and tirzepatide with misleading claims comparing them to FDA-approved drugs.

    Medium
  21. SemaBio

    FDA warned SemaBio that its website sold compounded semaglutide and called it 'generic semaglutide,' a false or misleading claim.

    Low
  22. directmeds.com, Inc. dba DirectMeds

    FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.

    High risk
  23. Hims & Hers Health, Inc. dba Hims

    FDA warns Hims that compounded semaglutide website claims are false or misleading and misbrand the drugs.

    High risk
  24. MedClub by Dr. Jenn

    FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.

    High risk
  25. Mane & Steel, LLC. dba Mane & Steel

    FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.

    Low
  26. Lumimeds

    FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.

    High risk
  27. GLP-1 Solution

    GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.

    High risk
  28. ASN-LABS

    ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.

    High risk
  29. Body Good Studio

    FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.

    High risk
  30. Canada Med Stop

    Canada Med Stop marketed compounded semaglutide online as FDA-approved and generic, making the drugs misbranded.

    Medium
  31. All American Wellness

    FDA warned telehealth seller All American Wellness that its website wrongly compares compounded semaglutide and tirzepatide to Ozempic and Mounjaro.

    Low
  32. Healthy Male

    FDA warns Healthy Male that its website sells compounded tirzepatide with false or misleading 'clinically proven' weight-loss claims.

    Low
  33. Intimate Rose

    FDA warned Intimate Rose that its website sells compounded semaglutide and tirzepatide with misleading claims that they match approved drugs.

    High risk
  34. Invigorate Med Spa

    Invigorate Med Spa's website claimed compounded semaglutide and tirzepatide were Wegovy and Mounjaro, making them misbranded.

    Low
  35. Dr. Gater’s Weight Loss & Wellness

    Dr. Gater’s Weight Loss & Wellness marketed compounded semaglutide and tirzepatide with false or misleading FDA-approval and generic-Ozempic claims.

    Medium
  36. Remedy Meds

    FDA warns Remedy Meds that its telehealth site misleadingly labels pharmacy-made semaglutide and tirzepatide with approved-drug comparisons.

    Low
  37. EA WORKS Limited Liability Company dba Trust Labs

    FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.

    High risk
  38. Fancy Meds, LLC dba Fancy Meds

    FDA warns Fancy Meds that its compounded semaglutide and tirzepatide website claims are false or misleading.

    Low
  39. Matthew Stern, CEO MyStart Health LLC.

    FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.

    Low
  40. Alora Pharmaceuticals

    FDA says Alora's paid search ads for RELEXXII ADHD drug are false or misleading because they omit risk information.

    Low
  41. Elite Health Center

    FDA warned Elite Health Center that its website falsely implied compounded semaglutide was FDA-approved, making the drugs misbranded.

    Low
  42. Curex

    FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.

    High risk
  43. Healthon Inc. dba Healthon

    FDA warned Healthon over unapproved compounded semaglutide and tirzepatide sold online with false 'FDA-approved' and 'same as' claims.

    High risk
  44. CSL Behring

    FDA says CSL Behring's HIZENTRA TV ad overstates protection and plays down risks, misbranding the immune globulin biologic.

    Medium
  45. Eli Lilly and Company

    FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.

    High risk
  46. Novo Nordisk Inc.

    FDA says Novo Nordisk’s Oprah Winfrey video makes Wegovy, Ozempic and Victoza look safer than their labels allow.

    High risk
  47. Eli Lilly and Company

    FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.

    High risk
  48. Eli Lilly and Company

    FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.

    Low
  49. HED Technologies, LLC d/b/a Everything 420

    Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded

  50. unclelarrysmokes.com

    Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded